Please assess the completion status of the following clinical trial:

Trial Title: GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. Postmenopausal women (defined as last menstrual period \> 1 year ago or 6 months ago with FSH \>40) who have been diagnosed with breast cancer including in situ carcinoma (DCIS, LCIS)~3. Have self-identified GSM signs and objective symptoms on baseline screening~4. Patients already using Replens™ or coconut oil will have a two week washout period prior to starting study treatment.~5. Medical History review and Pelvic Exam by a board certified gynecologist for baseline assessment OR medical records review by a board certified gynecologist or delegated study staff to confirm diagnosis of GSM. If GSM is to be verified by medical record review, the sub-investigator will make the final determination of eligibility.~Exclusion Criteria:~1. Use of any estrogen containing product within 4 weeks prior to screening~2. Endometrial hyperplasia, endometrial cancer, or other gynecologic malignancy~3. Patients with non GSM related signs and symptoms as verified by a board certified gynecologist will be excluded.~4. Any concurrent illness or disorder that, per the opinion of the investigator, would preclude the patient from meeting the study requirements.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Replens and coconut oil (Type: OTHER): Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).